Libration with a country December Dece																CIC)MI	SF	OF	₹M			
L. POLICET INTELLES The COUNTRY COSTA RICA Day Development Service Servi																							
Second Part	SUSPE	CT ADVERSE I																					
Section Section Price											Τ			Τ	Т	Τ	Τ						
Second Part														_			<u></u>						
PRIVACY PRIVAC	1 DATIENT INITIALS	10 COUNTRY	,					$\overline{}$	1 6 DE	=ACTIO	NI ONI	eet.	1012		- LIEC	- K ALL	—						
PRILATE Specime Bactorions (including stocked and seasons) and supported by comment) Prilate Specimen Prilate Specimen Prilate Specimen	(first, last)		Day	Month Ye		_		Da	ay	Month	n.	Year	┪	Α	APPR	OPRIA	ATE TO						
Diarrhace [Diarrhoca] Case Description: ""This is an auto generated narrative"" Study ID: 828662-My Healthy Journey Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Lindguide 3.0 mg). Consciented and Additional Information Page) III. SUSPECT DRUG(S) INFORMATION 14. SUSPECT DRUG(S) (include sprenc rame) #1) Saxenda (linguide 6 mg/mL). Solution for injection, 6 mg/mL 15. DAILY DOSES) #1) 1.20 mg, qd #1) Subcutaneous 16. ROUTES, CE-ADMINISTRATION #1) For weight loss (Weight control) 18. THERAPY DATES(genero) #1) For weight loss (Weight control) 18. THERAPY DATES(genero) #1) Unknown III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION levelude floore used to treat needloss IV. MANUFACTURER INFORMATION 24. NAME AND ADDRESS OF MANUFACTURER NOWN Nordisk AS DESCRIPTION, NO. 1443348 25. NAME AND ADDRESS OF MANUFACTURER NOWN Nordisk AS DESCRIPTION (include sprence in the page of the property of the page of	PRIVACY			PRIVACY	Years	Female	kg	22	2	MA	Y	202	`I —										
Study ID: 828652-My Healthy Journey Study Reacond (Irrigativide a description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liragiluide 3.0 mg). (Continued on Additional Information Page) II. SUSPECT DRUG(S) INFORMATION 14. SUSPECT DRUG(S) INFORMATION 15. DALY DOSESS 11. Subsended (Irrigativide 6 mg/mL) Solution for injection, 6 mg/mL 15. DALY DOSESS 17. R SUSPECT DRUG(S) INFORMATION 16. ROUTESS OF ADMINISTRATION 18. THERAPY DURATION 19. THERA	Diarrhea [Diarrhoea]											PROLONGED INPATIENT HOSPITALISATION INVOLVED PERSISTENT OR SIGNIFICANT											
Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liragilutide 3.0 mg). (Continued on Additional Information Page) II. SUSPECT DRUG(\$) INFORMATION 15. SUSPECT DRUG(\$) INFORMATION 15. DAILY DOSE(\$) (Insulae genetic rame) 17. INDICATIONS) FOR USS 17. INDICATIONS FOR USS 17. INDICATIONS (Weight control) 18. THERAPY DURATION 19. THERAPY DURATION 19	Case Description	: ***This is an auto	gener	ated narrative)***																		
Study description: That title: This is a 40 weeks digital patient support program with flocus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liragitudic & 3.0 mg). It is SUSPECT DRUG(s) Include previous pr	Study ID: 828652	2-My Healthy Journ	еу													ATENI	ING						
OTHER III. SUSPECT DRUG(S) Introduce generic rame) OTHER III. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) III. SU	Study description: Trial title: This is a 40 weeks digital nations support program with focus on exercise										_	CONGENITAL											
1.5. DAILY DOSE(S) (Reduce genetic name) #1) Saxenda (Irraglutide 6 mg/mL) Solution for injection, 6 mg/mL 20. DID REACTION RAPE AFTER STOPPING DRUGY 15. DAILY DOSE(S) #1) Subcutaneous 16. ROUTE(S) OF ADMINISTRATION 17. NDICATIONS) FOR USE #1) Subcutaneous 21. DID REACTION REAPPEAR AFTER STOPPING DRUGY 17. NDICATIONS) FOR USE #1) Subcutaneous 21. DID REACTION REAPPEAR AFTER STOPPING DRUGY 17. NDICATIONS) FOR USE #1) MAY-2025 / Ongoing 18. THERAPY DURATION #1) Unknown 21. DID REACTION REAPPEAR AFTER REINFRONCHOOVER 22. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allegies, pregnancy with last month of particle, etc.) 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allegies, pregnancy with last month of particle, etc.) 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allegies, pregnancy with last month of particle, etc.) 22. DESCRIPTION 22. DESCRIPT	motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).										OTHER												
1.5. DAILY DOSE(S) (Reduce genetic name) #1) Saxenda (Irraglutide 6 mg/mL) Solution for injection, 6 mg/mL 20. DID REACTION RAPE AFTER STOPPING DRUGY 15. DAILY DOSE(S) #1) Subcutaneous 16. ROUTE(S) OF ADMINISTRATION 17. NDICATIONS) FOR USE #1) Subcutaneous 21. DID REACTION REAPPEAR AFTER STOPPING DRUGY 17. NDICATIONS) FOR USE #1) Subcutaneous 21. DID REACTION REAPPEAR AFTER STOPPING DRUGY 17. NDICATIONS) FOR USE #1) MAY-2025 / Ongoing 18. THERAPY DURATION #1) Unknown 21. DID REACTION REAPPEAR AFTER REINFRONCHOOVER 22. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allegies, pregnancy with last month of particle, etc.) 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allegies, pregnancy with last month of particle, etc.) 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allegies, pregnancy with last month of particle, etc.) 22. DESCRIPTION 22. DESCRIPT				II. SUSP	ECT DR	UG(S) IN	FORMA [*]	TIO	N														
15. DAILY DOSE(S) #1) 1.20 mg, qd	14. SUSPECT DRUG(S) (include generic name)															STOP	PING						
#1) 1.20 mg, qd #1) Subcutaneous	#1) Saxenda (IIra(giutide 6 mg/mL) Soi	ution to	or injection, 6	mg/mL									RU	G?								
#1) For weight loss (Weight control) 18. THERAPY DATES(from/tio)														YES NO NA									
19. THERAPY DURATION																rer							
#1) MAY-2025 / Ongoing #1) Unknown	#1) For weight lo	ss (Weight control)																					
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown 1V. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmenshave Vandtaarnsvej 114 Soeborg, DA:2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 25a. REPORT SOURCE STUDY LITERATURE LITERATUR														YES NO NA									
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE 15c. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. 25c. NAME AND ADDRESS WITHHELD.			III	I. CONCOI	MITANT	DRUG(S) AND H	IST	OR	Υ			1										
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE BY MANUFACTURER STUDY LITERATURE BY THIS REPORT 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	22. CONCOMITANT DRU	UG(S) AND DATES OF ADM	MINISTRA	ATION (exclude tho	se used to treat	reaction)																	
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE BY MANUFACTURER STUDY LITERATURE BATTO THIS REPORT 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																							
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE BY MANUFACTURER STUDY LITERATURE BATTO THIS REPORT 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																							
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE BY MANUFACTURER STUDY LITERATURE BATTO THIS REPORT 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																							
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE 25b. NAME AND ADDRESS WITHHELD.	From/To Dates	HISTORY. (e.g. diagnostics																					
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE	OTIKHOWIT																						
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE DATE OF THIS REPORT 25a. REPORT TYPE 26. REMARKS Medically Confirmed: No 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																							
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE DATE OF THIS REPORT 25a. REPORT TYPE 26. REMARKS Medically Confirmed: No 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																							
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE				\/ \/ \/ \/		וחבט וגיי		-104															
Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE Medically Confirmed: No 45b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	24a. NAME AND ADDRESS OF MANUFACTURER 26. REMARKS												—		—								
1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 DATE OF THIS REPORT 25a. REPORT TYPE AMME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE	Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK						Medically Confirmed: No																
1443348 24c. DATE RECEIVED BY MANUFACTURER 23-MAY-2025 DATE OF THIS REPORT 25a. REPORT TYPE AMME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE		24h MER CC	NTROL I	NO.		25h NA	ME AND ADDE	RESS (OF RF	₽ORT	=R				_		_						
23-MAY-2025																							
23-MAY-2025	24c. DATE RECEIVED BY MANUFACTURE	24d. REPOR	T SOURC		DE																		
DATE OF THIS REPORT 25a. REPORT TYPE		Malana	SSIONAI	Ш	KE																		
		Γ 25a. REPOR			ID.																		

Mfr. Control Number: 1443348

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Patient's height: 155 cm.

Patient's weight: 76.2 kg.

Patient's BMI: 31.71696150.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "Diarrhea(Diarrhea)" beginning on 22-MAY-2025, "Vomiting(Vomiting)" beginning on 22-MAY-2025 and concerned a 23 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from MAY-2025 and ongoing for "For weight loss",

Dosage Regimens:

Saxenda: ??-MAY-2025 to Not Reported (Dosage Regimen Ongoing);

Medical history was not provided.

Batch Numbers:

Saxenda: ASKU:

Action taken to Saxenda was Not reported.

On 23-MAY-2025 the outcome for the event "Diarrhea(Diarrhea)" was Recovered. On 23-MAY-2025 the outcome for the event "Vomiting(Vomiting)" was Recovered.

Reporter's causality (Saxenda) -Diarrhea(Diarrhea) : Possible Vomiting(Vomiting) : Possible

Company's causality (Saxenda) -Diarrhea(Diarrhea) : Possible Vomiting(Vomiting) : Possible

Reporter Comment: The patient somewhat surprised and believes there may be interference from the foods that they consumed, particularly fatty foods.